
ãã¹ã¯ãšè·é¢
èšäºã®ãã£ãã
ãã®èšäºãæžãããšæã£ãçºç«¯ã¯ããããã¹ã¯ççšã«ããææãªã¹ã¯ã®äœæžã®è©±ã
Twitteräžã§ããããã€ãŒãããŠãã人ãããŠããäžç®ã§ãããããããŠãããªïŒããšæã£ãŠåºå žãèããªãã©ã€ãããŸããã
ãã®å ãšãªã£ããã€ãŒãã¯ããºã£ãŠçŸåšïŒïŒäžãããïŒãè¶ ããŠããŸãããã®ãã€ãŒãã«ã³ã¡ã³ãããã®ã§ãéç¥ããã®ïŒæ¥éãã£ãšäžå®æã«æ¥ç¶ããŠããŸãã
ãã¹ã¯ã¯å¿ é ïŒãã¹ã¯ãã€ããã®ã¯åžžèïŒäžã®äžãã¹ã¯ãã€ããŠããªã人ãªããŠããªããšæã£ãŠããããœãŒã·ã£ã«ãã£ã¹ã¿ã³ã¹ã¯åžžèïŒè·é¢ããšããªã人ãªããŠããªããšæã£ãŠããããããªåžžèãåžžèã§ãªããªã£ãŠããŠãããã ãªãšæããŸããã
ãã®ãã€ãŒããããºããšããããšã¯ããã¹ã¯ããã£ãšããŠã»ãããè·é¢ããã£ãšãšã£ãŠæ¬²ãããšæã£ãŠãã人ããããšããããšã ãšæããŸãã
åºå žã¯ã©ãïŒ
ã©ããªæ å ±ã§ãåºå žãã©ãããŠãæ°ã«ãªã£ãŠããŸããŸããå æ å ±ã¯
Facebookã®ãã®ãµã€ããšãã話ãããããŸããã
ãInternational Journal of Pharmaceutical Sciences and Researchã
ãããŠãã®äžã«
by Society of Pharmaceutical Sciences and Research
ãã®æ©é¢ãçºè¡ããŠããéèªãšããŠãJournal of Advanced Pharmaceutical Technology and ResearchïŒJ Adv Pharm Technol ResïŒãããããã§ããã2020幎çºè¡ã®æç®ãæ¢ããŠã該åœããããªãã®ã¯æ¢ããŸããã§ããã
ãè©°ãã ãªãããæ£çŽãªææ³ã§ãã
ãã¹ã¯ççšã®ãªã¹ã¯è»œæžã®æ ¹æ ãæ¢ã
ãã€ã¿ãŒã»ãã¡ã¯ãã»ãã§ãã¯
2020幎2æ12æ¥ããã€ã¿ãŒã¯æ°ããReuters Fact CheckïŒãã€ã¿ãŒã»ãã¡ã¯ãã»ãã§ãã¯ïŒäºæ¥ãšããã°ãã¹ã¿ãŒããããŠããŸãããœãŒã·ã£ã«ã¡ãã£ã¢ã®æªãããšå€æããæçš¿åç»ãåçãèšäºã審æ»ãããã€ã¿ãŒã»ãã¡ã¯ãã»ãã§ãã¯ã®ããã°ã§ããªãããããã§ã€ã¯ãªã®ããéšåçã«ãŠãœãªã®ããæ¬åœãªã®ããäžèЧã§è¡šç€ºãããŸããåãœãŒã·ã£ã«ã¡ãã£ã¢ã¯ãã®æ å ±ãåºã«åœæ å ±ã®æçš¿ãåãšãããããã«ã©ãã«ãä»ããæ¡æ£ãæå¶ããä»çµã¿ãšãªã£ãŠããããã§ãã
ãã®ãã€ã¿ãŒã»ãã¡ã¯ãã»ãã§ãã¯ïŒREUTERS FACT CHECKïŒã§2020.4.24ã«ãšããããããŠããå 容ããã¡ãã§ãã
ãã®ç»åã«å¯ŸããŠãã¡ã¯ããã§ãã¯ïŒäžéšèåœïŒãããã£ãŠããŸãã
ãã®è¡šç€ºãåºãŠãçç±ãèŠããã¯ãªãã¯ãããšã
ãã¡ã¯ããã§ãã¯ã®å 容ã衚瀺ãããŸãããã®ç»åã«å¯ŸããŠãïŒã€ã®ãã¡ã¯ããã§ãã¯ãããã£ãŠããŸããããä»åã¯ãã€ã¿ãŒã®ãã®ãã¿ãŠã¿ãŸãã
ãéšåçã«èª€ã£ã䞻匵ïŒãã§ã€ã¹ãã¹ã¯ãççšããããšã§ãCOVID-19ã®ææãªã¹ã¯ãæå€§98.5ïŒ
åæžã
ãã¹ã¯ãççšããŠããªãCOVID-19ä¿èè ãšãã¹ã¯ãççšããŠããéä¿èè ã®éã«ã¯70ïŒ ã®ææç¢ºçããããŸãããã¹ã¯ãççšããŠããCOVID-19ä¿èè ãšãã¹ã¯ãççšããŠããªãéä¿èè ãšã®éã«ã¯5ïŒ ã®ææç¢ºçããããŸãããŸããCOVID-19ä¿èè ãšéä¿èè ã®äž¡æ¹ããã¹ã¯ãççšããŠããå Žåã«ã¯1.5ïŒ ã®ææç¢ºçããããŸããïŒç«èšŒãããŠããªãå 容ïŒ
ããã€ã¿ãŒã¯ãããã®å²åãè£ä»ãã蚌æ ãèŠã€ããããšãã§ããªãã£ããšèšèŒããŠããŸãããã€ã¿ãŒéä¿¡ã¯ç±³åœçŸç
察çã»ã³ã¿ãŒïŒCDCïŒã«ã確èªããŠããŸãããCDCã®åºå ±æ
åœè
ã¯ãããã®ç»åã«åæ ãããŠããæ°å€ã®æ£ç¢ºãã確èªã§ãããçŸåšã®ãšãããã¹ã¯ã®äœ¿çšã«ãããªã¹ã¯ã®äœæžãå®éåã§ããããŒã¿ã¯èŠã€ãã£ãŠããªãããšåçããŠããŸãã
ãŸãå¥ã®ãã¡ã¯ããã§ãã¯ã®èšäºã«ãããŠãããå³ã«ç€ºãããŠãããªã¹ã¯ã®çžå¯Ÿçãªé åºã¯æ£ããããå®éã®æ°ã¯ãã±ãŒã¹ãŸãã¯ä¿èè ã«ãã£ãŠæµåºããããŠã€ã«ã¹ã®æ°ã2人ã®å人éã®è·é¢ããã¹ã¯ã®æè³ªã«ãã£ãŠãç°ãªãããšèšèŒãããŠããŸãã
èŠããã«ãæ°åã®æ ¹æ ã¯ãªããããªã¹ã¯äœæžã®é åºã¯æ£ãã
ãšãããäžéšèåœã®çµè«ã«ãªã£ãŠããŸãã
äœè«ã§ããããã ã¹ã¿ãŒã«å¯ŸããŠãã¹ã¯å¹æãæ€èšŒããæç®ã¯ããããã®äžã§ã¯ææãªã¹ã¯ã®äœæžãæ°å€ã§è¡šçŸã§ããŠããŸãã
ãèšäºã®ã³ã¡ã³ã
ç©ççãªè·é¢ããã¹ã¯ã¯COVID-19ææãåçã«æžããããšãã§ããŸãïŒLancetã®èšäºããã®ã³ã¡ã³ããèšèŒãããŠããŸãã
ä»ã®äººãã3ãã£ãŒãé¢ããå Žæã«ãããšãäŒæã®ãªã¹ã¯ãæšå®12.8ïŒ ãã2.6ïŒ æªæºã«äžããå¯èœæ§ãããã6ãã£ãŒãã®è·é¢ã¯1.5ïŒ ã«ãã®ãªã¹ã¯ãäžããããšãã§ããããŸãããã¹ã¯ãççšãããšããªã¹ã¯ãçŽ17.4ïŒ ããçŽ3.1ïŒ ã«æžããããšãã§ãããšèšèŒãããŠããŸãã
ã®èãæ¹
CDCïŒCenters for Disease Control and PreventionïŒç±³åœçŸç 察çã»ã³ã¿ãŒïŒã®è©²åœããŒãžãâ
ãã®åžè£œãã¹ã¯ã®èãæ¹ã
â å ¬å ±ã®å Žããäžåž¯ä»¥å€ã®äººãšã®ç€ŸäŒçè·é¢ãç¶æããããšãå°é£ãªå Žåã«ãåžè£œãã¹ã¯ãççšããããšããå§ãããŸãã
â åžè£œãã¹ã¯ã¯ãCOVID-19ææè ãä»ã®äººã«ãŠã€ã«ã¹ãåºããã®ãé²ãã®ã«åœ¹ç«ã¡ãŸãã
â 2æ³æªæºã®åäŸããåŒåžã«åé¡ããããæèããªããç¡åã§ããããŸãã¯æ¯æŽãªãã«ãã¹ã¯ãå€ãããšãã§ããªã人ã¯ãåžè£œãã¹ã¯ãççšããªãã§ãã ããã
ãã®ãã§ã€ã¹ã·ãŒã«ãã®èãæ¹ã
âéåžžã®æ¥åžžæŽ»åã§ã®ãã§ã€ã¹ã·ãŒã«ãã®äœ¿çšããåžè£œãã¹ã¯ã®ä»£çšãšããŠã®äœ¿çšãæšå¥šããŠããªãã
âãã§ã€ã¹ã·ãŒã«ãããã¹ã¯ãªãã§äœ¿çšãããå Žåããã§ã€ã¹ã·ãŒã«ãã¯ççšè ã®é¡ã®åŽé¢ãå ã¿èŸŒã¿ãããã®äžãŸã§å±ãããã«ããªããã°ãªããªãã
âäœ¿ãæšãŠã®ãã§ã€ã¹ã·ãŒã«ãã¯ãäžåºŠã ãã®äœ¿çšã«éãççšãã¹ãã§ãããåå©çšå¯èœãªãã§ã€ã¹ã·ãŒã«ãã¯ãå䜿çšåŸã«æŽæµã»æ¶æ¯ããå¿ èŠããããŸãã
âæ°çå ã幌å ã®ããã®ãã©ã¹ããã¯è£œã®ãã§ã€ã¹ã·ãŒã«ãã¯æšå¥šãããŠããŸããã
ãåžè£œãã¹ã¯ççšã«é¢ããäŸå€ãã»èŽèŠé害è
ãèŽèŠé害è
ããŸãã¯èŽèŠé害è
ã®äžè©±ã亀æµãããŠãã人ã
ãã³ãã¥ãã±ãŒã·ã§ã³ã«èªåè¡ã䜿çšããŠããå Žåãåžè£œã®ãã¹ã¯ãççšã§ããªãå ŽåããããŸãããã®ç¶æ³ã§ã¯ããã§ã€ã¹ã«ããŒã䜿çšããããšãæ€èšããŠãã ããããã§ã€ã¹ã«ããŒãå©çšã§ããªãå Žåã¯ãå£ãåžã§ãµãããªãããæžé¢ã«ããã³ãã¥ãã±ãŒã·ã§ã³ãåå¹ã®äœ¿çšãªã©ãæ€èšããŠãã ããã
ã»ããŒããããŒã«ã§æ³³ãã§ãããšã
ãåžè£œè¡šé¢ãã¹ã¯ãæ¿¡ããå¯èœæ§ã®ããæŽ»åã«åŸäºããŠãããšãã¯ãåžè£œãã¹ã¯ãççšããªãã§ãã ãããæ¿¡ããåžã¯ãåŒåžãå°é£ã«ããããšããããŸããæ°Žæ³³ãªã©ã§ã¯ãæ°Žäžã«ãããšãã«ä»ã®äººãšã®ç©ççãªè·é¢ãç¶æããããšãç¹ã«éèŠã§ãã
ã»ã©ã³ãã³ã°ãªã©ã®æ¿ããéåãããŠãã人
ãåŒåžå°é£ã®åå ãšãªããããåžè£œã®ãã¹ã¯ãççšã§ããªãå ŽåããããŸããççšã§ããªãå Žåã¯ãææ°ãšç©ºæ°äº€æã®å€ãå ŽæïŒå±å€ãšå±å
ãªã©ïŒã§ãä»ã®äººãšã®ç©ççãªè·é¢ãç¶æã§ããå Žæã§æŽ»åãè¡ãããšãæ€èšããŠãã ããã
ã»åžè£œãã¹ã¯ãç±äžçã®ãªã¹ã¯ãå¢å ããããããã¹ã¯ã®çŽãæ©æ¢°ã«å·»ã蟌ãŸããçå®å
šäžã®æžå¿µãããç°å¢ã§äœæ¥ãã人
ãåŽåå®å
šè¡çã®å°éå®¶ã«çžè«ããŠé©åãªé¡ã«ããŒã決å®ããããšãã§ããŸãã
ãããã«
çµå±ããªã¹ã¯è»œæžã®æ°åã®æ ¹æ ã«ãªã£ãŠããæç®ã¯æ¢ããŸããã§ããããïœïœïœïœ ïœã®èšäºããããããããã«ãïŒãã£ãŒãïŒçŽïŒã¡ãŒãã«ïŒã®è·é¢ãä¿ã€ããšããã¹ã¯ãççšããããšã¯ç¢ºå®ã«ææãªã¹ã¯ãäœæžãããããšã¯ééããªãããããœãŒã·ã£ã«ãã£ã¹ã¿ã³ã¹ããã¹ã¯ççšã¯çã§æèããŠä»åŸãåãçµãã§ããããã§ããã
仿Žã§ããããã®èšäºãæžããŠããŠãæåã«è©±é¡ãšããŠæããç»åã®äžããïŒçªç®ã®ïŒ²ïœïœïœã¯ïŒïŒïŒ ã§ã¯ãªããïŒïŒïŒ ã§ã¯ãªããããïŒãšæããŸããã
ãã£ã¡ãé¡ã«é£æ²«ããã£ãŠãŸããããã






